A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia.

Autor: Nørskov KH; Department of Haematology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen Ø, Denmark. Electronic address: kristina.holmegaard.noerskov@regionh.dk., Fridthjof K; Amgros, Dampfærgevej 22, 2100, Copenhagen Ø, Denmark. Electronic address: ksf@amgros.dk., Kampmann P; Department of Haematology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen Ø, Denmark. Electronic address: Peter.Kampmann@regionh.dk., Dünweber A; Department of Haematology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen Ø, Denmark. Electronic address: Anne.Duenweber@regionh.dk., Andersen CL; Department of Haematology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen Ø, Denmark. Electronic address: christen.bertel.lykkegaard.andersen@regionh.dk., Renaberg T; Department of Haematology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen Ø, Denmark. Electronic address: toni.petrea.renaberg@regionh.dk., Schöllkopf C; Department of Haematology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen Ø, Denmark. Electronic address: claudia.schoellkopf.01@regionh.dk., Ahmad SA; Department of Haematology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen Ø, Denmark. Electronic address: syed.azhar.ahmad.01@regionh.dk., Schou K; Department of Haematology, Zealand University Hospital, Sygehusvej 10, 4000, Roskilde, Denmark. Electronic address: katrs@regionsjaelland.dk., Jensen CF; Department of Haematology, Zealand University Hospital, Sygehusvej 10, 4000, Roskilde, Denmark. Electronic address: cecf@regionsjaelland.dk., Møller P; Department of Haematology, Zealand University Hospital, Sygehusvej 10, 4000, Roskilde, Denmark. Electronic address: pml@regionsjaelland.dk., Lundholm BW; Department of Hematology, Odense University Hospital, J. B. Winsløws Vej 4, 5000, Odense C, Denmark. Electronic address: birgitte.wolf.lundholm@rsyd.dk., Marcher C; Department of Hematology, Odense University Hospital, J. B. Winsløws Vej 4, 5000, Odense C, Denmark. Electronic address: claus.marcher@rsyd.dk., Jepsen L; Department of Hematology, Odense University Hospital, J. B. Winsløws Vej 4, 5000, Odense C, Denmark. Electronic address: Lene.Jepsen@rsyd.dk., Ørntoft AK; Department of Hematology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus C, Denmark. Electronic address: An.Oern@auh.rm.dk., Ommen HB; Department of Hematology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus C, Denmark. Electronic address: hans.beier.ommen@rm.dk., Andersen L; Department of Hematology, Aalborg University Hospital, Hobrovej 18-22, 9000, Aalborg, Denmark. Electronic address: lotte.andersen@rn.dk., Behrentzs A; Department of Hematology, Aalborg University Hospital, Hobrovej 18-22, 9000, Aalborg, Denmark. Electronic address: anni.behrentzs@rn.dk., Hasselgren CF; Department of Hematology, Aalborg University Hospital, Hobrovej 18-22, 9000, Aalborg, Denmark. Electronic address: cfh@rn.dk., Severinsen M; Department of Hematology, Aalborg University Hospital, Hobrovej 18-22, 9000, Aalborg, Denmark. Electronic address: m.severinsen@rn.dk., Grand MK; Department of Public Health, University of Copenhagen, Øster Farimagsgade 5, 1014, Copenhagen K, Denmark. Electronic address: migra@sund.ku.dk., Jarden M; Department of Haematology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen Ø, Denmark; Department of Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen N, Copenhagen, Denmark. Electronic address: mary.jarden@regionh.dk., Møller T; University Hospital Center for Health Research, Ryesgade 27, 2200, Copenhagen N, Denmark. Electronic address: tom.moeller@regionh.dk., Kjeldsen L; Department of Haematology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen Ø, Denmark. Electronic address: lars.kjeldsen.01@regionh.dk.
Jazyk: angličtina
Zdroj: Leukemia research [Leuk Res] 2022 Jan; Vol. 112, pp. 106756. Date of Electronic Publication: 2021 Nov 22.
DOI: 10.1016/j.leukres.2021.106756
Abstrakt: Technological advances have made it possible to offer home-based chemotherapy to patients without health care professionals being present. Prior studies on effects of home-based treatment lack inclusion of patients with hematologic malignancies. We present data from a multicenter single-arm feasibility and safety study of home-based intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia and their quality of life and psychological wellbeing. This national study included patients from six sites in Denmark who received intensive chemotherapy on programmed CADD Solis infusion pumps through a central venous catheter and were also managed as outpatients during treatment-induced pancytopenia. Data are presented from 104 patients, receiving 272 treatments with 1.096 (mean 4.57, SD 3.0) home infusion days out of 1.644 treatment days (67 %). Sixty-two of 168 (36.9 %) reinduction and consolidation treatment cycles ensuing pancytopenia phases were solely handled in the outpatient clinic. Patients reported high satisfaction with home-based treatment, which had a positive influence on their ability to be involved in their treatment and be socially and physically active. No unexpected events occurred during the intervention. Overall, patients improved in all quality of life outcomes over time. Home-based intensive chemotherapy treatment was feasible and safe in this population. ClinicalTrials.gov identifier: NCT04904211.
(Copyright © 2021 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: